KR20190123351A - 개질된 올리고뉴클레오티드 및 이의 치료 용도 - Google Patents

개질된 올리고뉴클레오티드 및 이의 치료 용도 Download PDF

Info

Publication number
KR20190123351A
KR20190123351A KR1020197030864A KR20197030864A KR20190123351A KR 20190123351 A KR20190123351 A KR 20190123351A KR 1020197030864 A KR1020197030864 A KR 1020197030864A KR 20197030864 A KR20197030864 A KR 20197030864A KR 20190123351 A KR20190123351 A KR 20190123351A
Authority
KR
South Korea
Prior art keywords
compound
protein
pharmaceutical composition
moiety
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197030864A
Other languages
English (en)
Korean (ko)
Inventor
알렉산더 롤로프
나탄 씨. 지안네스키
카산드라 이. 콜먼
매튜 피. 톰프슨
폴 에이. 버틴
Original Assignee
더 리젠츠 오브 더 유니버시티 오브 캘리포니아
바이빌 홀딩스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 리젠츠 오브 더 유니버시티 오브 캘리포니아, 바이빌 홀딩스, 인코포레이티드 filed Critical 더 리젠츠 오브 더 유니버시티 오브 캘리포니아
Publication of KR20190123351A publication Critical patent/KR20190123351A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020197030864A 2017-03-22 2018-03-21 개질된 올리고뉴클레오티드 및 이의 치료 용도 Ceased KR20190123351A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762475185P 2017-03-22 2017-03-22
US62/475,185 2017-03-22
PCT/US2018/023578 WO2018175592A1 (en) 2017-03-22 2018-03-21 Modified oligonucleotides and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
KR20190123351A true KR20190123351A (ko) 2019-10-31

Family

ID=63586170

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197030864A Ceased KR20190123351A (ko) 2017-03-22 2018-03-21 개질된 올리고뉴클레오티드 및 이의 치료 용도

Country Status (9)

Country Link
US (1) US20200046846A1 (enExample)
EP (1) EP3600439A4 (enExample)
JP (1) JP2020514383A (enExample)
KR (1) KR20190123351A (enExample)
CN (1) CN110636865A (enExample)
AU (1) AU2018237139A1 (enExample)
CA (1) CA3057292A1 (enExample)
SG (1) SG11201908771YA (enExample)
WO (1) WO2018175592A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250270248A1 (en) * 2020-09-16 2025-08-28 Astrazeneca Ab Oligonucleotides conjugated to fatty acids
CN117980003A (zh) * 2021-09-10 2024-05-03 嘉德治疗有限责任公司 核酸的脂肪酸缀合物
WO2025028656A1 (ja) * 2023-08-02 2025-02-06 日東電工株式会社 オリゴヌクレオチドを製造する方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0821001A4 (en) * 1995-03-31 2002-07-17 Drug Delivery System Inst Ltd AMIDITY DERIVATIVES AND OLIGONUCLEOTIDE DERIVATIVES
US8969543B2 (en) * 2003-04-03 2015-03-03 Bioneer Corporation SiRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof
WO2007112414A2 (en) * 2006-03-27 2007-10-04 Isis Pharmaceuticals, Inc. Conjugated double strand compositions for use in gene modulation
KR101224828B1 (ko) * 2009-05-14 2013-01-22 (주)바이오니아 ｓｉＲＮＡ 접합체 및 그 제조방법
GB0910723D0 (en) * 2009-06-22 2009-08-05 Sylentis Sau Novel drugs for inhibition of gene expression
CN103649311A (zh) * 2011-06-03 2014-03-19 国立大学法人北海道大学 寡核苷酸衍生物、包含寡核苷酸衍生物的治疗用医药组合物及诊断用医药组合物、以及miRNA机能抑制用寡核苷酸衍生物
RU2599449C1 (ru) * 2011-12-15 2016-10-10 Байонир Корпорейшн Новые конъюгаты олигонуклеотидов и их применение
DK3019200T3 (da) * 2013-07-11 2022-06-20 Alnylam Pharmaceuticals Inc Oligonukleotid-ligand-konjugater og fremgangsmåde til fremstiling deraf
CN105792851B (zh) * 2013-09-13 2023-10-10 斯克利普斯研究所 修饰的治疗剂及其组合物
AU2014364589B2 (en) * 2013-12-18 2020-02-27 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
JP6773677B2 (ja) * 2015-03-17 2020-10-21 アローヘッド ファーマシューティカルズ インコーポレイテッド 改善されたジスルフィド含有アルキン連結剤
MA41794A (fr) * 2015-03-18 2018-01-23 The California Institute For Biomedical Res Agents thérapeutiques modifiés et compositions associées
WO2017030973A1 (en) * 2015-08-14 2017-02-23 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
AU2016326392B2 (en) * 2015-09-22 2021-02-11 The Regents Of The University Of California Modified cytotoxins and their therapeutic use

Also Published As

Publication number Publication date
AU2018237139A1 (en) 2019-10-17
EP3600439A1 (en) 2020-02-05
CN110636865A (zh) 2019-12-31
JP2020514383A (ja) 2020-05-21
SG11201908771YA (en) 2019-10-30
WO2018175592A1 (en) 2018-09-27
US20200046846A1 (en) 2020-02-13
EP3600439A4 (en) 2021-01-13
CA3057292A1 (en) 2018-09-27

Similar Documents

Publication Publication Date Title
US9968686B2 (en) Antisense oligonucleotides with improved pharmacokinetic properties
US12084661B2 (en) Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
US11840691B2 (en) Compound and application thereof
CN104781271B (zh) 具有生物可逆的基团的多核苷酸
US20220395526A1 (en) Nucleic acid, composition and conjugate containing same, and preparation method and use
US11918600B2 (en) Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof
JP7190794B2 (ja) 核酸医薬及び多分岐脂質の複合体
CN103764169B (zh) 用于非病毒转移核酸的全氟化化合物
EP3978609A1 (en) Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
KR20220012284A (ko) 핵산, 약학 조성물, 컨쥬게이트와 이의 제조 방법 및 용도
TW202227135A (zh) 用於遞送治療劑之脂質結合物
US20250223594A1 (en) Modified double-stranded oligonucleotide molecule, modified double-stranded oligonucleotide conjugate, and use thereof
KR20190123351A (ko) 개질된 올리고뉴클레오티드 및 이의 치료 용도
CN111246855A (zh) 用于分子的跨膜递送的化合物和方法
CN116133691A (zh) 与脂肪酸缀合的寡核苷酸
Honcharenko et al. New alkyne and amine linkers for versatile multiple conjugation of oligonucleotides
ES3030929T3 (en) Arnatar compounds and methods for enhanced cellular uptake
CN104185478B (zh) 用于靶向递送至表达lfa-1的细胞的整联蛋白拮抗剂缀合物
US20060142232A1 (en) Oligomeric compositions and methods
AU2020398192A1 (en) Peptide docking vehicle for targeted nucleic acid delivery
JP2024533427A (ja) 核酸の脂肪酸コンジュゲート
CA2761752A1 (en) Polycationic amphiphilic cyclooligosaccharides and the use thereof as molecular transporters
EP3974529A1 (en) Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
US20110237499A1 (en) Hybrid tripyrrole-octaarginine compounds and their use as medicament in the treatment of cancer and microbial illnesses
WO2025232840A1 (zh) GalNAc衍生物及其寡聚核苷酸缀合物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191018

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210316

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230904

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20231110

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230904

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I